Skip to main content
Clinical Trials/CTRI/2019/10/021760
CTRI/2019/10/021760
Active, not recruiting
Phase 4

A long-term non-interventional observational study in Living Donor Liver Transplant Recipients (LDLTRs) with primary hepatocellular carcinoma (HCC) treated with Certican® / Zortress® (everolimus; EVR) plus reduced tacrolimus (rTAC) versus standard tacrolimus (sTAC) control

ovartis Healthcare Pvt Ltd0 sites1 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: K742- Hepatic fibrosis with hepatic sclerosis
Sponsor
ovartis Healthcare Pvt Ltd
Enrollment
1
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
ovartis Healthcare Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients who have completed 24 month RCT study CRAD001H2307 and had primary HCC at the time of liver transplantation.
  • 2\. Patient who signed the informed consent to participate in this NIS.

Exclusion Criteria

  • 1\. Patient with a liver graft loss during the 2 years in the CRAD001H2307 study.

Outcomes

Primary Outcomes

Not specified

Similar Trials